8-K filing — Genprex, Inc. (GNPX)
Filed: 2026-10-28 AccNo: 0001437749-26-033700 Size: 167 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Stocks · News reference
Genprex Partners With Roche Diagnostics To Validate Biomarkers For Patient Selection In Clinical Trials For Non-Small Cell Lung Cancer
Building on promising preclinical and clinical data, this collaboration intends to refine patient identification using TROP2 as a biomarker. Genprex's initial research demonstrated that high TROP2 H-scores and low
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Genprex Reports New Preclinical Data on TUSC2 Gene
Genprex, Inc. announced new preclinical findings regarding the role of the TUSC2 gene in cellular function during brain aging.
Genprex Highlights New Peer-Reviewed Research In Mice Identifying Important Role For TUSC2 Tumor Suppressor Gene In Maintaining Cellular Processes Associated With Healthy Brain Aging
Collaborators publish new peer-reviewed study identifying sex-specific effects of TUSC2 loss on mitochondrial function, protein homeostasis, and synaptic pathways, alongside molecular similarities with human
Genprex Announces Development And Manufacturing Agreement With Undisclosed U.S. CDMO To Scale Up cGMP Production Of Diabetes Gene Therapy For IND-Enabling Studies, Future Trials